GSK executive acquires notional ADS in savings plan

GSK plc reported that President Maya Martinez-Davis acquired notional American Depositary Shares through her GSK Executive Supplemental Savings Plan account.

Rhea-AI Filing Summary

GSK plc reported that President Maya Martinez-Davis acquired notional American Depositary Shares through her GSK Executive Supplemental Savings Plan account. The plan transaction on 2026-04-07 involved 8.551 ADS at a price of $55.8400 per ADS on the New York Stock Exchange.

Key Figures

ADS price: $55.8400 per ADS ADS volume: 8.551 ADS Transaction date: 2026-04-07

3 metrics

ADS price $55.8400 per ADS Price per American Depositary Share on 7 April 2026

ADS volume 8.551 ADS Notional ADS acquired in single plan transaction

Transaction date 2026-04-07 Date of notional ADS acquisition on NYSE (XNYS)

Key Terms

American Depositary Shares, Executive Supplemental Savings Plan, PDMR, notional ADS

4 terms

American Depositary Shares financial

"Description of the financial instrument | American Depositary Shares ('ADS') ISIN: US37733W2044"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Executive Supplemental Savings Plan financial

"Acquisition of notional ADS within Ms Martinez-Davis's GSK Executive Supplemental Savings Plan account."

PDMR regulatory

"Details of PDMR/person closely associated with them ('PCA')"

A PDMR (person discharging managerial responsibilities) is an individual who can shape a company’s strategy or finances—typically senior executives, board members, or close advisors with decision-making authority. Investors care because PDMRs often hold material, non‑public information and their buying or selling of shares must be reported; monitoring those disclosures is like watching a ship’s captain to read the likely course and spot possible insider risk.

notional ADS financial

"Acquisition of notional ADS within Ms Martinez-Davis's GSK Executive Supplemental Savings Plan account."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GSK (GSK) disclose in this report?

GSK disclosed that President Maya Martinez-Davis acquired 8.551 notional American Depositary Shares at $55.8400 each. The acquisition occurred within her GSK Executive Supplemental Savings Plan account and was executed on the New York Stock Exchange on 7 April 2026.

Who is the GSK (GSK) executive involved in the April 2026 ADS transaction?

The executive is Maya Martinez-Davis, a President at GSK plc. She acquired notional American Depositary Shares within her GSK Executive Supplemental Savings Plan account, as reported for a single transaction dated 7 April 2026 on the New York Stock Exchange.

What type of security did the GSK (GSK) executive acquire?

Maya Martinez-Davis acquired notional American Depositary Shares (ADS) of GSK plc, identified by ISIN US37733W2044. These ADS represent an interest in GSK’s equity and were credited within her GSK Executive Supplemental Savings Plan account as part of an internal savings arrangement.

At what price were the GSK (GSK) ADS acquired in this transaction?

The notional American Depositary Shares were acquired at a price of $55.8400 per ADS. This price applied to the entire reported volume of 8.551 ADS credited within Maya Martinez-Davis’s GSK Executive Supplemental Savings Plan account on 7 April 2026.

Where and when was the GSK (GSK) ADS transaction carried out?

The transaction took place on the New York Stock Exchange, identified as XNYS. It occurred on 7 April 2026 and involved a single acquisition of 8.551 notional American Depositary Shares at $55.8400 each, within an executive supplemental savings plan account.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/09/2026 - 12:38 PM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Maya Martinez-Davis
b)	Position/status	President, US
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of notional ADS within Ms Martinez-Davis's GSK Executive Supplemental Savings Plan account.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$55.8400	8.551
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-04-07
f)	Place of the transaction	New York Stock Exchange (XNYS)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: April 09, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc